- Home
- OMAB vs LEGN Comparison
OMAB vs LEGN Comparison
Compare OMAB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMAB
- LEGN
- Stock Information
- Founded
- OMAB 1998
- LEGN 2014
- Country
- OMAB Mexico
- LEGN United States
- Employees
- OMAB N/A
- LEGN N/A
- Industry
- OMAB Aerospace
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- OMAB Consumer Discretionary
- LEGN Health Care
- Exchange
- OMAB Nasdaq
- LEGN Nasdaq
- Market Cap
- OMAB 4.8B
- LEGN 5.4B
- IPO Year
- OMAB 2006
- LEGN 2020
- Fundamental
- Price
- OMAB $99.26
- LEGN $28.95
- Analyst Decision
- OMAB Buy
- LEGN Strong Buy
- Analyst Count
- OMAB 4
- LEGN 12
- Target Price
- OMAB $102.50
- LEGN $77.09
- AVG Volume (30 Days)
- OMAB 87.8K
- LEGN 1.9M
- Earning Date
- OMAB 07-25-2025
- LEGN 05-13-2025
- Dividend Yield
- OMAB 4.58%
- LEGN N/A
- EPS Growth
- OMAB 2.49
- LEGN N/A
- EPS
- OMAB 0.65
- LEGN N/A
- Revenue
- OMAB $728,352,552.00
- LEGN $728,303,000.00
- Revenue This Year
- OMAB $6.46
- LEGN $64.21
- Revenue Next Year
- OMAB $12.84
- LEGN $53.69
- P/E Ratio
- OMAB $19.01
- LEGN N/A
- Revenue Growth
- OMAB N/A
- LEGN 112.46
- 52 Week Low
- OMAB $59.08
- LEGN $27.34
- 52 Week High
- OMAB $102.74
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- OMAB 64.92
- LEGN 41.56
- Support Level
- OMAB $95.19
- LEGN $28.13
- Resistance Level
- OMAB $98.62
- LEGN $29.31
- Average True Range (ATR)
- OMAB 2.51
- LEGN 1.63
- MACD
- OMAB -0.70
- LEGN 0.03
- Stochastic Oscillator
- OMAB 64.16
- LEGN 27.01
About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS
Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, individually, and information about its holding company and other companies is combined in the Others.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.